Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.

abstract：:Immunotherapy with oncolytic herpes simplex virus-1 therapy offers an innovative, targeted, less-toxic approach for treating brain tumors. However, a major obstacle in maximizing oncolytic virotherapy is a lack of comprehensive understanding of the underlying mechanisms that unfold in CNS tumors/associated microenviro...

journal_title：Oncoimmunology

authors： Bernstock JD,Vicario N,Rong L,Valdes PA,Choi BD,Chen JA,DiToro D,Osorio DS,Kachurak K,Gessler F,Johnston JM Jr,Atkinson TP,Whitley RJ,Bag AK,Gillespie GY,Markert JM,Maric D,Friedman GK

更新日期：2019-10-21 00:00:00

abstract：:PolyI:C is a nucleotide pattern molecule that induces cross-presentation of foreign Ag in myeloid dendritic cells (DC) and MHC Class I-dependent proliferation of cytotoxic T lymphocytes (CTL). DC (BM or spleen CD8α(+)) have sensors for dsRNA including polyI:C to signal facilitating cross-presentation. Endosomal TLR3 a...

journal_title：Oncoimmunology

authors： Azuma M,Ebihara T,Oshiumi H,Matsumoto M,Seya T

更新日期：2012-08-01 00:00:00

abstract：:VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation...

journal_title：Oncoimmunology

authors： Schmitz-Winnenthal FH,Hohmann N,Schmidt T,Podola L,Friedrich T,Lubenau H,Springer M,Wieckowski S,Breiner KM,Mikus G,Büchler MW,Keller AV,Koc R,Springfeld C,Knebel P,Bucur M,Grenacher L,Haefeli WE,Beckhove P

更新日期：2018-01-16 00:00:00

abstract：:DNA damage responses have been proposed as a gatekeeper to block tumorigenesis. We identify unexpected mechanisms whereby ATM-mediated pathway interacts with NFκB inflammatory cascades, leading to upregulation of integrin-αbβ3 on chemoresistant tumor cells. The integrin-αbβ3 is responsible for impeding tumor-specific ...

journal_title：Oncoimmunology

authors： Jinushi M

更新日期：2012-05-01 00:00:00

abstract：:Pancreatic tumors are rich in immune cell infiltrates that include CD4+ T-cell subsets encompassing both regulatory T cells and TH17 cells. Rather than protecting the organism by exerting an anticancer effect, these T-cell subsets promote tumor formation. Thus, re-activation of antitumor immunity should be investigate...

journal_title：Oncoimmunology

authors： Zhang Y,McAllister F,Pasca di Magliano M

更新日期：2014-06-05 00:00:00

abstract：:Targeting antigens directly to dendritic cells (DCs) in situ has emerged as a promising strategy to potentiate immunity. A recent clinical trial of antibody-mediated targeting of tumor antigen NY-ESO1 to the DC receptor DEC-205 demonstrated an induction of strong cellular and humoral responses. Recent studies with DC-...

journal_title：Oncoimmunology

authors： Dhodapkar MV,Dhodapkar KM

更新日期：2014-08-03 00:00:00

abstract：:A Phase I trial of a p53-targeting modified vaccinia Ankara (p53MVA) vaccine in patients afflicted with refractory gastrointestinal cancers demonstrated enhanced T-cell recognition of p53 following vaccination. However, this effect was transient suggesting that p53MVA requires combination with immunomodulatory agents ...

journal_title：Oncoimmunology

authors： Hardwick N,Chung V,Cristea M,Ellenhorn JD,Diamond DJ

更新日期：2014-12-15 00:00:00

abstract：:By merging computational systems modeling and experimental approaches, we have uncovered treatments reprogramming pro-angiogenic monocytes present in breast tumor into immunologically potent cells capable of mediating an anti-tumor immune response. The unraveled pathways and ligands which underlie monocyte pro-angioge...

journal_title：Oncoimmunology

authors： Doucey MA,Xenarios I

更新日期：2015-07-07 00:00:00

abstract：:Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigate...

journal_title：Oncoimmunology

authors： Ferretti E,Di Carlo E,Ognio E,Guarnotta C,Bertoni F,Corcione A,Prigione I,Fraternali-Orcioni G,Ribatti D,Ravetti JL,Ponzoni M,Tripodo C,Pistoia V

更新日期：2015-06-19 00:00:00

abstract：:The inspection of the mechanisms through which autophagy modulates immunogenic cell death revealed that the autophagic response of cancer cells to reactive oxygen species-dependent endoplasmic reticulum stress suppresses the exposure of calreticulin on the cell surface, the phenotypic maturation of dendritic cells (DC...

journal_title：Oncoimmunology

authors： Garg AD,Dudek AM,Agostinis P

更新日期：2013-10-01 00:00:00

abstract：:A major advantage of immunotherapy of cancer is that effector cells induced at one site should be able to kill metastatic cancer cells in other sites or tissues. However, different tissues have unique immune components, and very little is known about whether effector T cells induced against tumors in one tissue can wo...

journal_title：Oncoimmunology

authors： O'Konek JJ,Ambrosino E,Bloom AC,Pasquet L,Massilamany C,Xia Z,Terabe M,Berzofsky JA

更新日期：2018-04-09 00:00:00

abstract：:We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma. Twenty-four patients previously untreated with checkpoint blockade were enrolled. The agonistic CD40 mAb CP-870,893 and the CT...

journal_title：Oncoimmunology

authors： Bajor DL,Mick R,Riese MJ,Huang AC,Sullivan B,Richman LP,Torigian DA,George SM,Stelekati E,Chen F,Melenhorst JJ,Lacey SF,Xu X,Wherry EJ,Gangadhar TC,Amaravadi RK,Schuchter LM,Vonderheide RH

更新日期：2018-08-20 00:00:00

abstract：:Under physiological conditions, PD-1/PD-L1 interactions regulate unwanted over-reactions of immune cells and contribute to maintain peripheral tolerance. However, in tumor microenvironment, this interaction may greatly compromise the immune-mediated anti-tumor activity. PD-1+ NK cells have been detected in high percen...

journal_title：Oncoimmunology

authors： Mariotti FR,Petrini S,Ingegnere T,Tumino N,Besi F,Scordamaglia F,Munari E,Pesce S,Marcenaro E,Moretta A,Vacca P,Moretta L

更新日期：2018-12-25 00:00:00

abstract：:Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytot...

journal_title：Oncoimmunology

authors： Adamopoulou E,Naumann U

更新日期：2013-08-01 00:00:00

abstract：:We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-es...

journal_title：Oncoimmunology

authors： Kebenko M,Goebeler ME,Wolf M,Hasenburg A,Seggewiss-Bernhardt R,Ritter B,Rautenberg B,Atanackovic D,Kratzer A,Rottman JB,Friedrich M,Vieser E,Elm S,Patzak I,Wessiepe D,Stienen S,Fiedler W

更新日期：2018-04-18 00:00:00

abstract：:By analyzing CD4+ lymphocytes in human breast carcinomas, we have recently uncovered the presence of follicular helper T cells in lesions exhibiting an extensive immune infiltrate. The presence of these specialized CD4+ T cells, which localize to the germinal centers of peritumoral tertiary lymphoid structures found i...

journal_title：Oncoimmunology

authors： Gu-Trantien C,Willard-Gallo K

更新日期：2013-10-01 00:00:00

abstract：:The prognosis of high-risk neuroblastoma (NB) remains poor, although immunotherapies with anti-GD2 antibodies have been reported to provide some benefit. Immunotherapies can be associated with an IFNγ storm that induces in tumor cells the "adaptive immune resistance" characterized by the de-novo expression of Programm...

journal_title：Oncoimmunology

authors： Dondero A,Pastorino F,Della Chiesa M,Corrias MV,Morandi F,Pistoia V,Olive D,Bellora F,Locatelli F,Castellano A,Moretta L,Moretta A,Bottino C,Castriconi R

更新日期：2015-07-15 00:00:00

abstract：:Immunotherapy with immune checkpoint molecule-specific monoclonal antibody have obtained encouraging results from preclinical studies and clinical trials, which promoted us to explore whether this kind of immunotherapy could be applicable to head and neck squamous cell carcinoma (HNSCC). Lymphocyte activation gene-3 (...

journal_title：Oncoimmunology

authors： Deng WW,Mao L,Yu GT,Bu LL,Ma SR,Liu B,Gutkind JS,Kulkarni AB,Zhang WF,Sun ZJ

更新日期：2016-10-07 00:00:00

abstract：:Macrophages in the tumor microenvironment respond to complex cytokine signals. How these responses shape the phenotype of tumor-associated macrophages (TAMs) is incompletely understood. Here we explored how cytokines of the tumor milieu, interleukin (IL)-6 and IL-4, interact to influence target gene expression in prim...

journal_title：Oncoimmunology

authors： Gupta S,Jain A,Syed SN,Snodgrass RG,Pflüger-Müller B,Leisegang MS,Weigert A,Brandes RP,Ebersberger I,Brüne B,Namgaladze D

更新日期：2018-07-30 00:00:00

abstract：:Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges that are even more significant. In order to devise a treatment strategy for patients with glioblastoma...

journal_title：Oncoimmunology

authors： Suryadevara CM,Desai R,Abel ML,Riccione KA,Batich KA,Shen SH,Chongsathidkiet P,Gedeon PC,Elsamadicy AA,Snyder DJ,Herndon JE 2nd,Healy P,Archer GE,Choi BD,Fecci PE,Sampson JH,Sanchez-Perez L

更新日期：2018-02-21 00:00:00

abstract：:Cell signals integral to the tumor microenvironment influence cancer progression. Tumor-associated myeloid cells secrete pro-tumorigenic agents including, but not limited to, the potent cytokine transforming growth factor β (TGFβ). We have discovered a network of extrinsic signals including delta-like 4 (Dll4), Notch ...

journal_title：Oncoimmunology

authors： Ohnuki H,Tosato G

更新日期：2014-05-23 00:00:00

abstract：:Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerfu...

journal_title：Oncoimmunology

authors： Baragaño Raneros A,López-Larrea C,Suárez-Álvarez B

更新日期：2018-10-31 00:00:00

abstract：:Regulatory T cell (Treg) promote IL-17-mediated colon tumorigenesis in multiple intestinal neoplasia (Min) mice colonized with enterotoxigenic Bacteroides fragilis (ETBF). Although they retain their immunosuppressive function, mucosal Treg are instrumental to initiate ETBF-triggered IL-17 colitis by limiting the avail...

journal_title：Oncoimmunology

authors： Geis AL,Housseau F

更新日期：2015-12-21 00:00:00

abstract：:In many cancers, regulatory T cells (Treg) play a crucial role in suppressing the effector immune response thereby permitting tumor development. Indeed, in mouse models, their depletion can promote the regression of tumors of various origins, including renal cell carcinoma when located subcutaneous (SC). In the presen...

journal_title：Oncoimmunology

authors： Devaud C,Westwood JA,Teng MW,John LB,Yong CS,Duong CP,Smyth MJ,Darcy PK,Kershaw MH

更新日期：2014-12-21 00:00:00

abstract：:Prostate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile oncolytic virus capable of lethally infecting a variety of prostatic tumor cell lin...

journal_title：Oncoimmunology

authors： Atherton MJ,Stephenson KB,Tzelepis F,Bakhshinyan D,Nikota JK,Son HH,Jirovec A,Lefebvre C,Dvorkin-Gheva A,Ashkar AA,Wan Y,Stojdl DF,Belanger EC,Breau RH,Bell JC,Saad F,Singh SK,Diallo JS,Lichty BD

更新日期：2018-03-27 00:00:00

abstract：:Immunotherapeutic strategies including the blockade of programmed death 1 (PD-1) receptors hold promise for the treatment of various cancers including non-small cell lung carcinoma (NSCLC). Preclinical data suggest that pre-existing tumor immunity is important for disease regression upon checkpoint blockade-based ther...

journal_title：Oncoimmunology

authors： Dhodapkar KM,Gettinger SN,Das R,Zebroski H,Dhodapkar MV

更新日期：2013-07-01 00:00:00

abstract：:The programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) pathway has emerged as a critical inhibitory pathway regulating T-cell response in non-small-cell lung cancer (NSCLC), and the development of PD-1/PD-L1 inhibitors has changed the landscape of NSCLC therapy. Nevertheless, the high degree of non-responders demons...

journal_title：Oncoimmunology

authors： Raimondi C,Carpino G,Nicolazzo C,Gradilone A,Gianni W,Gelibter A,Gaudio E,Cortesi E,Gazzaniga P

更新日期：2017-04-20 00:00:00

abstract：:Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood. Here, we show that oncolysis of mesothelioma by modified vaccinia Tiantan (MVTT) induces damage-associated molecular patterns exposure. A...

journal_title：Oncoimmunology

authors： Tan Z,Liu L,Chiu MS,Cheung KW,Yan CW,Yu Z,Lee BK,Liu W,Man K,Chen Z

更新日期：2018-10-16 00:00:00

abstract：:Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing. Chimeric antigen receptors (CARs) couple the HLA-independent binding of a cell surface target to the...

journal_title：Oncoimmunology

authors： Thayaparan T,Petrovic RM,Achkova DY,Zabinski T,Davies DM,Klampatsa A,Parente-Pereira AC,Whilding LM,van der Stegen SJ,Woodman N,Sheaff M,Cochran JR,Spicer JF,Maher J

更新日期：2017-08-14 00:00:00

abstract：:The B7 family and tumor necrosis factor receptor (TNFR) superfamily play a vital role in the T-cell co-stimulatory and co-inhibitory pathways, regulating T-cell activation, tolerance, and exhaustion; therapeutic modulation of these pathways is translated into effective new cancer treatments. Better understanding of th...

journal_title：Oncoimmunology

authors： Chen YP,Zhang J,Wang YQ,Liu N,He QM,Yang XJ,Sun Y,Ma J

更新日期：2017-02-16 00:00:00